HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

NCT07530198 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus
Human Immunodeficiency Virus I Infection

Interventions

BIOLOGICAL: ICVAX (TERESA-EPT I device)
BIOLOGICAL: ICVAX (PharmaJet Tropis device)
BIOLOGICAL: ICVAX (TriGrid device)

Sponsor

Immuno Cure Holding (HK) Limited

Collaborators

[object Object]
[object Object]